CD38 and plasma cell myeloma: After the three main classes of drugs for MM (proteasome inhibitors [PI], immunomodulatory imide drugs [IMiD], and anti-CD38 monoclonal antibodies [CD38 mAb]) have failed patients, few effective options remain for relapsed/refractory multiple myeloma (RRMM).